Novartis AG/€NOVN
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Novartis AG
Novartis AG is a global healthcare company based in Switzerland, specializing in the research, development, manufacturing, and marketing of a broad range of pharmaceutical products. The company's core business is centered around patented prescription medicines in areas such as oncology, cardiovascular, immunology, neuroscience, and ophthalmology. Formed in 1996 from the merger of Ciba-Geigy and Sandoz, Novartis operates in over 150 countries worldwide. Its strategic positioning is reinforced by significant investments in research and development, supporting a robust pipeline of innovative therapies. The company is headquartered in Basel, Switzerland, and emphasizes its competitive strength through advanced research capabilities and a diverse product portfolio.
Ticker
€NOVN
Sector
Primary listing
XGAT
Employees
75,883
Headquarters
Basel, Switzerland
Website
Novartis AG Metrics
BasicAdvanced
€205B
18.24
€5.84
0.53
€3.65
3.43%
Price and volume
Market cap
€205B
Beta
0.53
52-week high
€111.68
52-week low
€86.43
Average daily volume
7.1K
Dividend rate
€3.65
Financial strength
Current ratio
0.818
Quick ratio
0.502
Long term debt to equity
57.222
Total debt to equity
77.607
Dividend payout ratio (TTM)
57.26%
Interest coverage (TTM)
17.47%
Profitability
EBITDA (TTM)
20,073.37
Gross margin (TTM)
76.28%
Net profit margin (TTM)
24.74%
Operating margin (TTM)
34.76%
Effective tax rate (TTM)
12.62%
Revenue per employee (TTM)
€622,170
Management effectiveness
Return on assets (TTM)
11.88%
Return on equity (TTM)
32.49%
Valuation
Price to earnings (TTM)
18.235
Price to revenue (TTM)
4.478
Price to book
4.56
Price to tangible book (TTM)
-14.94
Price to free cash flow (TTM)
14.651
Free cash flow yield (TTM)
6.83%
Free cash flow per share (TTM)
7.266
Dividend yield (TTM)
3.43%
Forward dividend yield
3.43%
Growth
Revenue change (TTM)
12.95%
Earnings per share change (TTM)
-12.59%
3-year revenue growth (CAGR)
4.33%
10-year revenue growth (CAGR)
0.70%
3-year earnings per share growth (CAGR)
-12.58%
10-year earnings per share growth (CAGR)
-1.49%
3-year dividend per share growth (CAGR)
4.34%
10-year dividend per share growth (CAGR)
3.97%
Bulls say / Bears say
Novartis raised its full-year 2025 core operating income growth outlook to low teens after Q2 adjusted operating income climbed 20% and sales rose 12%, powered by strong performances from Kisqali, Kesimpta and Entresto, alongside a new $10 billion share buyback.
Switzerland approved Coartem Baby on July 8, 2025—the first malaria treatment for infants under 4.5 kg—addressing an urgent need in pediatric care across eight African countries.
On March 13, 2025, the FDA approved Kisqali for first-line treatment of HR+/HER2- advanced or metastatic breast cancer, enabling Novartis to compete directly with Pfizer’s Ibrance and pursue a multi-billion-dollar market.
Novartis lost its effort to block generic Entresto, which lets MSN Pharmaceuticals launch a lower-cost alternative as early as July 16, 2025, threatening the $7.8 billion heart-failure business.
Q2 sales of Cosentyx for psoriasis fell short of analyst forecasts, raising concerns about the company’s ability to drive growth outside of its oncology drugs.
The announced $23 billion plan to expand U.S. manufacturing facilities poses execution risks and could pressure free cash flow if tariff relief is delayed.
Data summarised monthly by Lightyear AI. Last updated on 1 Sept 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Novartis AG stock?
Novartis AG (NOVN) has a market cap of €205B as of September 15, 2025.
What is the P/E ratio for Novartis AG stock?
The price to earnings (P/E) ratio for Novartis AG (NOVN) stock is 18.24 as of September 15, 2025.
Does Novartis AG stock pay dividends?
Yes, the Novartis AG (NOVN) stock pays dividends to shareholders. As of September 15, 2025, the dividend rate is €3.6508 and the yield is 3.43%. Novartis AG has a payout ratio of 57.26% on a trailing twelve-month basis.
When is the next Novartis AG dividend payment date?
The next Novartis AG (NOVN) dividend payment date is unconfirmed.
What is the beta indicator for Novartis AG?
Novartis AG (NOVN) has a beta rating of 0.53. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.